Wegovy dosage
The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly. For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.
Word for word from the FDA label on DailyMed (Novo Nordisk Pharmaceutical Industries, LP), revised , version 19. Read every day: a new FDA version updates this page by itself.
Wegovy dosage chart
The soonest the label's schedule allows. A clinician can go slower.
| Injection | Dose |
|---|---|
| Weeks 1 to 4 | 0.25 mg |
| Weeks 5 to 8 | 0.5 mg |
| Weeks 9 to 12 | 1 mg |
| Weeks 13 to 16 | 1.7 mg |
| Week 17 on | 2.4 mg |
| After at least 4 weeks on 2.4 mg | 7.2 mgif tolerated and more weight loss is indicated |
| Tablet | Dose |
|---|---|
| Days 1 to 30 | 1.5 mg |
| Days 31 to 60 | 4 mg |
| Days 61 to 90 | 9 mg |
| Day 91 on | 25 mg |
Wegovy dosing and administration
Important Monitoring and Administration Instructions
In patients with diabetes mellitus, monitor blood glucose prior to starting WEGOVY and during WEGOVY treatment [see Warnings and Precautions (5.4)].
Administer WEGOVY in combination with a reduced-calorie diet and increased physical activity.
WEGOVY Injection
- Inform patients and their caregiver(s) which WEGOVY presentation (e.g., single-dose pen or syringe, or WEGOVY FlexTouch single-patient-use pen) they will receive and ensure they receive training appropriate for that specific presentation. If the prescribed WEGOVY presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation.
- Prior to initiation, train patients and their caregiver(s) on proper injection technique for the prescribed WEGOVY presentation [see Instructions for Use ] . After training, a patient may self-inject WEGOVY if the healthcare provider determines that it can be properly administered, except for the following: o WEGOVY FlexTouch is not recommended for self-administration by those who are visually impaired.
- Visually inspect the WEGOVY injection prior to each administration. Only use if the solution is clear, colorless, and contains no particles.
- Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals.
- Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm. The time of day and the injection site can be changed without the need for a dosage modification.
- Rotate injection sites with each dose.
WEGOVY Tablets
- Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). Do not take WEGOVY tablets with other liquids besides water [see Clinical Pharmacology (12.3)].
- Swallow tablets whole. Do not split, crush, chew or dissolve in any solution.
- Do not take more than one tablet per day.
- After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications [see Clinical Pharmacology (12.3)].
Recommended Dosage for WEGOVY Injection
Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications
- The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.
- Follow the dosage escalation in Table 1 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)].
- If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks.
Table 1. Recommended Starting Dosage and Dosage Escalation of WEGOVY Injection for All Approved Indications in Adults and Pediatric Patients Aged 12 Years and Older
| Weeks | Once-weekly Subcutaneous Injection Dosage | |
| Starting Dosage | 1 through 4 | 0.25 mg |
| Dosage Escalation | 5 through 8 | 0.5 mg |
| 9 through 12 | 1 mg | |
| 13 through 16 | 1.7 mg | |
| Maintenance Dosage | 17 and onward | See the indication below for the recommended maintenance dosage(s) |
Recommended Maintenance Dosage of WEGOVY Injection for All Approved Indications
Cardiovascular Risk Reduction in Adults
- The maintenance dosage of WEGOVY injection for cardiovascular risk reduction in adults is either 2.4 mg (recommended) or 1.7 mg once weekly.
- Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions (6.1), Clinical Studies (14.1)].
Weight Reduction in Adults
- The maintenance dosage of WEGOVY for weight reduction in adults is either 1.7 mg or 2.4 mg (recommended) injected subcutaneously once weekly.
- For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.
- Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions ( 6.1 ), Clinical Studies ( 14.2 )].
Weight Reduction in Pediatric Patients Aged 12 Years and Older
- The maintenance dosage of WEGOVY injection for weight reduction in pediatric patients aged 12 years and older is either 2.4 mg (recommended), or 1.7 mg once weekly.
- Consider treatment response and tolerability when selecting the maintenance dosage [see Adverse Reactions ( 6.1 ), Clinical Studies ( 14.3 )] .
Noncirrhotic MASH with Moderate to Advanced Liver Fibrosis in Adults
- The recommended maintenance dosage of WEGOVY injection for the treatment of noncirrhotic MASH with moderate to advanced liver fibrosis in adults is 2.4 mg injected subcutaneously once weekly. If patients do not tolerate the maintenance dosage of 2.4 mg once weekly, the dosage can be decreased to 1.7 mg once weekly. Consider reescalation to 2.4 mg once weekly [see Adverse Reactions ( 6.1 ), Clinical Studies ( 14.4 )] .
Recommended Dosage of WEGOVY Tablets
Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults
- The recommended starting dosage of WEGOVY tablets is 1.5 mg taken orally once daily. Follow the dosage escalation in Table 2 to reduce the risk of gastrointestinal adverse reactions [see Warnings and Precautions (5.6), Adverse Reactions (6.1)].
- If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation.
- The recommended maintenance dosage of WEGOVY tablets is 25 mg orally once daily.
- If patients do not tolerate the 25 mg once daily maintenance dosage, consider switching to WEGOVY injection 1.7 mg once weekly [see Dosage and Administration (2.5)].
Table 2. Recommended Dosage of WEGOVY Tablets for Cardiovascular Risk Reduction or Weight Reduction in Adults
| Days | Once Daily Tablet Dosage | |
| Starting Dosage | 1 through 30 | 1.5 mg |
| Dosage Escalation | 31 through 60 | 4 mg |
| 61 through 90 | 9 mg | |
| Maintenance Dosage | 91 and onward | 25 mg |
Recommendations Regarding Missed Dose(s)
WEGOVY Injection
- If one dose of WEGOVY injection is missed and the next scheduled dose is:
- more than 2 days away, administer WEGOVY injection as soon as possible.
- less than 2 days away, do not administer the WEGOVY injection dose. Resume dosing on the regularly scheduled day of the week.
- If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.2), Warnings and Precautions ( 5.6 ), Adverse Reactions (6.1)].
WEGOVY Tablets
If a dose of WEGOVY tablets is missed, skip the missed dose and take the next dose the following day.
Switching Between WEGOVY Injection and WEGOVY Tablets
Switching from WEGOVY Injection to WEGOVY Tablets
- Patients taking WEGOVY 2.4 mg injection for cardiovascular risk reduction or weight reduction in adults may switch to WEGOVY 25 mg tablets.
- One week after discontinuing WEGOVY 2.4 mg injection, initiate 25 mg of WEGOVY tablets orally once daily.
Switching from WEGOVY Tablets to WEGOVY Injection
- Patients may switch from WEGOVY 25 mg tablets to WEGOVY injection.
- The day after discontinuing WEGOVY tablets 25 mg once daily, initiate WEGOVY 2.4 mg subcutaneous injection once weekly. For patients who do not tolerate WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection.
- If additional weight reduction is needed in patients with type 2 diabetes mellitus treated with WEGOVY 25 mg tablets, consider switching to WEGOVY 1.7 mg injection and follow the recommended dosage escalation for WEGOVY injection [see Dosage and Administration (2.2), Use in Specific Populations (8.6), Clinical Pharmacology (12.3)].
Source: Wegovy prescribing information (FDA label on DailyMed), revised 2026-06-18
Wegovy strengths and forms
Injection: clear, colorless solution available as follows:
| Single-Dose Pens | Single-Dose Pens |
|---|---|
| Dose per Injection | Total Strength per Total Volume |
| 0.25 mg | 0.25 mg/0.5 mL |
| 0.5 mg | 0.5 mg/0.5 mL |
| 1 mg | 1 mg/0.5 mL |
| 1.7 mg | 1.7 mg/0.75 mL |
| 2.4 mg | 2.4 mg/0.75 mL |
| 7.2 mg (WEGOVY HD) | 7.2 mg/0.75 mL |
| Single-Patient-Use Pen (4 doses per Pen) (WEGOVY FlexTouch) | Single-Patient-Use Pen (4 doses per Pen) (WEGOVY FlexTouch) |
|---|---|
| Dose per Injection | Total Strength per Total Volume |
| 2.4 mg | 9.6 mg/3 mL (3.2 mg/mL) |
| Single-Dose Syringes | Single-Dose Syringes |
|---|---|
| Dose per Injection | Total Strength per Total Volume |
| 0.25 mg | 0.25 mg/0.5 mL |
| 0.5 mg | 0.5 mg/0.5 mL |
| 1 mg | 1 mg/0.5 mL |
| 1.7 mg | 1.7 mg/0.75 mL |
| 2.4 mg | 2.4 mg/0.75 mL |
Tablets: available as:
| Tablet Strength | Description |
|---|---|
| 1.5 mg | White to light yellow, round shaped debossed with “1.5” on one side and “novo” on the other side |
| 4 mg | White to light yellow, round shaped debossed with “4” on one side and “novo” on the other side |
| 9 mg | White to light yellow, round shaped debossed with “9” on one side and “novo” on the other side |
| 25 mg | White to light yellow, oval shaped debossed with “25” on one side and “novo” on the other side |
Source: Wegovy prescribing information (FDA label on DailyMed), revised 2026-06-18
How to store Wegovy
WEGOVY Injection
How Supplied
WEGOVY injection is a clear, colorless solution available in cartons containing 4 single-dose pens, 4 single-dose syringes with integrated needles, or 1 single-patient-use pen (WEGOVY FlexTouch) as follows:
| Device Type | Name | Total Strength per Total Volume | NDC |
|---|---|---|---|
| Single-dose Pen | WEGOVY | 0.25 mg/0.5 mL | 0169-4525-14 |
| Single-dose Pen | 0.5 mg/0.5 mL | 0169-4505-14 | |
| Single-dose Pen | 1 mg/0.5 mL | 0169-4501-14 | |
| Single-dose Pen | 1.7 mg/0.75 mL | 0169-4517-14 | |
| Single-dose Pen | 2.4 mg/0.75 mL | 0169-4524-14 | |
| Single-dose Pen | WEGOVY HD | 7.2 mg/0.75 mL | 0169-4572-14 |
| Single-patient-use Pen (with 4 weekly doses of 2.4 mg) | WEGOVY FlexTouch | 9.6 mg/3 mL (3.2 mg/mL) | 0169-4915-32 |
| Single-dose Syringe | WEGOVY | 0.25 mg/0.5 mL | 0169-1602-14 |
| Single-dose Syringe | 0.5 mg/0.5 mL | 0169-1605-14 | |
| Single-dose Syringe | 1 mg/0.5 mL | 0169-1610-14 | |
| Single-dose Syringe | 1.7 mg/0.75 mL | 0169-1617-14 | |
| Single-dose Syringe | 2.4 mg/0.75 mL | 0169-1624-14 |
Recommended Storage
- Do not store WEGOVY in the freezer or directly adjacent to the refrigerator cooling element.
- Do not freeze WEGOVY and do not use if it has been frozen.
Single-dose Pen or Single-dose Syringe Storage
Store the WEGOVY prefilled single-dose pen or single-dose syringe in the refrigerator from 2°C to 8°C (36°F to 46°F). If needed, prior to the pen or syringe cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days. Protect WEGOVY injection from light. WEGOVY injection must be kept in the original carton until time of administration. Discard the WEGOVY pen or syringe after use.
Single-patient-use Pen (WEGOVY FlexTouch) Storage
Prior to first use, store WEGOVY FlexTouch single-patient-use pen in a refrigerator between 2°C to 8°C (36°F to 46°F). After first use, WEGOVY FlexTouch single-patient-use pen can be stored for 56 days between 15°C to 30°C (59°F to 86°F) or in a refrigerator 2°C to 8°C (36°F to 46°F). WEGOVY FlexTouch single-patient-use pen should be protected from excessive heat and light. Keep the pen cap on when not in use. Always remove and safely discard the needle after each injection. Store the WEGOVY FlexTouch single-patient-use pen without an injection needle attached. Always use a new needle for each injection.
WEGOVY Tablets
How Supplied
WEGOVY tablets are available as:
| Tablet strength | Description | Package Configuration | NDC Number |
|---|---|---|---|
| 1.5 mg | White to light yellow, round shaped debossed with “1.5” on one side and “novo” on the other side | Bottle of 30 tablets | 0169-4415-31 |
| 4 mg | White to light yellow, round shaped debossed with “4” on one side and “novo” on the other side | Bottle of 30 tablets | 0169-4404-31 |
| 9 mg | White to light yellow, round shaped debossed with “9” on one side and “novo” on the other side | Bottle of 30 tablets | 0169-4409-31 |
| 25 mg | White to light yellow, oval shaped debossed with “25” on one side and “novo” on the other side | Bottle of 30 tablets | 0169-4425-31 |
Recommended Storage
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store and dispense WEGOVY tablets in the original bottle. Store WEGOVY tablet in the original bottle until use to protect tablets from moisture. Store WEGOVY tablets in a dry place away from moisture.
Source: Wegovy prescribing information (FDA label on DailyMed), revised 2026-06-18
Wegovy dosing: common questions
What should you expect in the first week of Wegovy?
From its FDA label: The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly. Your clinician may adjust this.
Can you skip a week of Wegovy?
Its FDA label covers a missed dose, not a planned break, so ask your prescriber before skipping one on purpose. On a missed dose it says: If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.
Can you drink coffee after taking Wegovy?
Not straight away. Its FDA label says: After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.
What is the starting dose of Wegovy?
The recommended starting dosage of WEGOVY injection is 0.25 mg administered subcutaneously once weekly.
What is the maximum or maintenance dose of Wegovy?
For patients who tolerate the 2.4 mg dosage for at least 4 weeks and additional weight reduction is clinically indicated, the dosage may be increased to a maximum dosage of 7.2 mg subcutaneously once weekly.
What if you miss a dose of Wegovy?
If 2 or more consecutive doses of WEGOVY injection are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions.
How long can Wegovy stay out of the fridge?
If needed, prior to the pen or syringe cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days.
Where do you inject Wegovy?
Inject WEGOVY subcutaneously in the abdomen, thigh, or upper arm.
When should you take Wegovy?
Administer WEGOVY injection once weekly, on the same day each week, at any time of day, with or without meals. Take one WEGOVY tablet orally once daily on an empty stomach in the morning with water (up to 4 ounces). After taking a WEGOVY tablet, wait at least 30 minutes before eating food, drinking beverages or taking other oral medications.
How do you use Wegovy?
From its FDA-approved Medication Guide: Use WEGOVY exactly as your healthcare provider tells you to. Use WEGOVY with a reduced-calorie diet and increased physical activity. If you take too much WEGOVY, you may have severe nausea, severe vomiting and severe low blood sugar. Call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Advice is also available online at poisonhelp.org. Read the Instructions for Use that comes with WEGOVY. Your healthcare provider should tell you which WEGOVY product you will be using (for example – single-dose pen or syringe, single-patient-use pen, or tablets). Before you use WEGOVY injection for the first time, your healthcare provider should show you how to use it. Once you have been trained, you may inject WEGOVY yourself if your healthcare provider determines that you are able to do so safely. If you are visually impaired, the WEGOVY FlexTouch pen is not recommended for self-injection. If you are prescribed a different WEGOVY product at any point, make sure you receive new training for the new product and read the Instructions for Use that come with it. WEGOVY is injected under the skin (subcutaneously) of your stomach (abdomen), thigh, or upper arm.
Dosing is decided by your clinician. This is the label's text for reference, not instructions for you.